On This Day in Health: March 19, 1987
On March 19, 1987, the United States Food and Drug Administration approved zidovudine, widely known as AZT and marketed as Retrovir, as the first authorized medicine for HIV. The National Institutes of Health's approval table records this date, even though March 20 appears in some accounts of the public announcement. The decision came during a devastating epidemic, when people with AIDS and those caring for them had few effective options. It offered a drug that could act against viral replication, while its limitations made clear that the arrival of one medicine did not mean the crisis had been solved.
AZT's history began before HIV was recognized. It had been developed in the 1960s as a potential cancer treatment and was later included in a National Cancer Institute program screening compounds against HIV. Laboratory findings led to human studies and pharmaceutical development. Zidovudine belongs to the nucleoside reverse transcriptase inhibitor class. These drugs interfere with an enzyme HIV uses to make copies of itself. That mechanism provided a way to slow the virus's activity, rather than simply treating infections that appeared after the immune system had been damaged.
Early clinical results showed benefits but also serious adverse effects. Anemia was among the significant problems reported during the initial era of treatment, and later research examined lower dosing and use before HIV had progressed to AIDS. Treatment with a single drug also faced the challenge of viral resistance. The continuing research program therefore had to ask more than whether AZT could have an effect: investigators needed to learn how medicines could be used effectively over time and how to reduce treatment-related harm. NIH's account of antiretroviral development places the first approval within that longer search for durable suppression.
Combination treatment became a major advance in the following decade, when using several medicines could suppress HIV more reliably and create a higher barrier to resistance. That later achievement helps explain both the significance and the limits of March 19. AZT opened a new phase of treatment research and care, but the path toward sustained control required additional drugs, trials, and changes in practice. The anniversary belongs to the people who participated in research, provided care, and pressed for access during a period of intense urgency. It marks a first regulatory foothold in antiviral treatment, whose historical importance is strongest when remembered alongside the difficult work that followed and the distinction between an early option and the more effective regimens developed later.
NIH's approval table gives March 19, 1987. Some announcement histories use March 20, so the regulatory date requires careful distinction.
AZT had earlier been investigated as a cancer treatment. HIV research gave the compound a different clinical purpose.
Zidovudine interferes with reverse transcriptase. It acts on viral replication rather than only on resulting opportunistic infections.
Early treatment produced benefit alongside serious adverse effects. Subsequent studies examined dosing and broader use.
Single-drug treatment faced resistance limitations. Durable control required further research and additional medicines.
The first approval began a new phase of care. Combination therapy in the following decade represented a separate major advance.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.